Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85784 | 0.91 | TAAR1 (0.53) | TAAR1FFAR1CYP2A6HTR2A | |
| SCHEMBL13962406 | 0.83 | TAAR1 (0.36) | TAAR1FFAR1GRM5CA12CA1 | |
| SCHEMBL10078124 | 0.81 | TAAR1 (0.45) | TAAR1HTR2AHTR7 | |
| SCHEMBL15805926 | 0.80 | TAAR1 (0.42) | TAAR1FFAR1CYP2A6HTR2A | |
| SCHEMBL6907499 | 0.77 | TAAR1 (0.50) | TAAR1CYP1A2CYP2A6HTR2ATACR1 | |
| SCHEMBL10119152 | 0.75 | TAAR1 (0.38) | TAAR1 | |
| Hydrochloric Acid SCHEMBL29548682 | 0.75 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6HTR2ATACR1 | |
| Hydrochloric Acid SCHEMBL6913336 | 0.75 | TAAR1 (0.48) | TAAR1CYP1A2CYP2A6HTR2ATACR1 | |
| SCHEMBL16169717 | 0.74 | GRM5 (0.34) | FFAR1GRM5CA12CA1CA2 | |
| SCHEMBL10198719 | 0.72 | TAAR1 (0.38) | TAAR1FFAR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160287586-A1 | COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS INFECTIONS | CELLCEUTIX CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | INNOVATION PHARMACEUTICALS INC. | 2016-07-28 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130252964-A1 | Compounds And Methods For Treating Candidiasis And Aspergillus Infections | POLYMEDIX, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013109827-A1 | COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS INFECTIONS | POLYMEDIX, INC. (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | TAAR1 4726/4885FFAR1 2257/4885CYP1A2 3438/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TAAR1 4726/4885FFAR1 2257/4885CYP1A2 3438/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TAAR1 2693/4885FFAR1 1192/4885CYP1A2 3099/4885 |
| US-20130252964-A1 | Compounds And Methods For Treating Candidiasis And Aspergillus Infections | ERG28, DPM1, MANBA | TAAR1 3777/4885FFAR1 3621/4885CYP1A2 218/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TAAR1 2693/4885FFAR1 1192/4885CYP1A2 3099/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | TAAR1 4831/4885FFAR1 3257/4885CYP1A2 2263/4885 |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | MUC1, SOST, ALG1 | TAAR1 3298/4885FFAR1 2021/4885CYP1A2 3404/4885 |
| US-20160287586-A1 | COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS INFECTIONS | ERG28, DPM1, MANBA | TAAR1 3777/4885FFAR1 3621/4885CYP1A2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.